Oncology Central

Utility of lymphatic invasion status for the prognosis of early non-small-cell lung cancer


Lymphatic invasion as a prognostic factor for non-small-cell lung cancer

The standard treatment for resectable stage I–IIIA non-small-cell lung cancer (NSCLC) is surgical resection. However, even with stage I NSCLC, patients sometimes develop a recurrence, with reported 5-year survival rates of 86.8% with stage IA and 73.9% with stage IB [1]. Although TNM classifications can stratify patients well into different prognosis groups, stage I NSCLC is still considered as a heterogeneous group.

Restricted Content / Members Only

You cannot view this content because It is available to members only. Please or Register to view this area.




News Headlines

Leave A Comment

Please wait...

Would you like access to more immuno-oncology content?

Register with Oncology Central to find out the latest news, opinions and journal articles published in the oncology field by leading experts.